CO HB1438

Adds deceptive trade practice violation under Colorado Consumer Protection Act for manufacturers failing to comply with insulin affordability program requirements under sections 12-280-139 and 12-280-140.

Transfers administration of insulin affordability and emergency insulin supply programs from Division of Insurance and Department of Health Care Policy and Financing to a newly created Board, with Attorney General authorized to enforce compliance.

Changes manufacturer penalties for noncompliance from fixed $10,000 monthly fines to variable fines equal to those permitted under the Colorado Consumer Protection Act.

Expands epinephrine auto-injector affordability program to require all manufacturers to participate, mandates multilingual application forms with QR codes accessible to pharmacies and individuals, and establishes point-of-sale electronic claim reimbursement standards.

Appropriates $8,874 from the Division of Professions and Occupations cash fund for 2024-25 fiscal year to support 0.2 FTE for program implementation.